Publicis forms Razorfish Healthware

Share this article:
Roberto Ascione
Roberto Ascione

The healthcare communications arm of Publicis Group is bringing two of its digital agencies together in a move designed to bolster them against the tide of healthcare advertising shops beefing up e-promotion capabilities.

The agencies, Razorfish Health and Publicis Healthware International, will unite as Razorfish Healthware. Razorfish Health, based in the US, and Healthware's 10 regional offices—which span the US, Europe and the Far East—will be re-branded under the new moniker.

Roberto Ascione, who has been president of Publicis Healthware International, will lead the 300-400-person entity. “Having scale in the US market, combined with this global reach, makes a very compelling unit overnight,” Ascione told MM&M.

The merger cuts the number of brands in the PHCG house from 11 to 10, including the digital agency Digitas Health. Rosetta, another purely digital shop with a healthcare practice, is part of Publicis Groupe's VivaKi unit.

The consolidation comes as more healthcare ad agencies are bringing on talent with digital skills and integrating services such as the ability to build websites and apps and execute tactics involving social media.

Given that agencies of record are building these skills, “There's a school of thought that says that the pure-play digital agency shouldn't exist any longer, but I believe there's a place for both,” Ascione acknowledged.

Razorfish Healthware will seek to develop strategies for companies that are moving into digital and will try to predict what experiences or paradigms medical professionals and consumers will want to engage in next, such as medically prescribed apps or drugs bundled with an app.

Both Ascione and Nick Colucci, president and CEO of PHCG, cited WellDoc's success in getting its DiabetesManager app approved by the FDA, and subsequently signing on payors, as an example of the kind of space Razorfish Healthware wants to get into. “We can be the company that will assist you to embrace the right technology to make that happen, the company that can provide the right consultancy services in order to transform your pharma company,” Ascione said
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets